about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
37.18
0.23
(0.62%)
1.0M
XNAS Volume
XNAS 21 Sep, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Neutral
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..